Treatment of relapsed or refractory Hodgkin’s lymphoma with lenalidomide combined with PD-1 monoclonal antibody: a case report and literature review

Treatment of relapsed or refractory Hodgkin’s lymphoma with lenalidomide combined with PD-1 monoclonal antibody: a case report and literature review

The current standard treatment for relapsed or refractory Hodgkin’s lymphoma involves salvage chemotherapy followed by high-dose chemotherapy and sequential autologous stem cell transplantation. However, for patients who cannot tolerate intense chemotherapy or do not meet the conditions for autologo...

Full description

Saved in:
Bibliographic Details
Main Authors: Hongjuan Dong, Rui Wang, Lu Cheng, Shirong Ma, Li Zhu, Jing Zhao, Guangxun Gao
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-07-01
Series:Frontiers in Oncology
Subjects:
Hodgkin lymphoma
lenalidomide
PD-1 monoclonal antibodies
relapsed/refractory
case report
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2025.1632039/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items